Osteoporosis: Disease severity and consequent fracture management

Osteoporosis International

Volumn 21, Issue SUPPL. 2, 2010, Pages 425-429

  Cooper, C ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Nonvertebral fracture; Osteopenia; Osteoporosis; Strontium ranelate; Vertebral fracture

Indexed keywords

PLACEBO; RALOXIFENE; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; STRONTIUM;

AGING; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; LIFE EXPECTANCY; MEDICAL HISTORY; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THORACOLUMBAR SPINE; VERTEBRA FRACTURE; AGED; FEMALE; MALE; METHODOLOGY; MIDDLE AGED;

AGED; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; STRONTIUM RADIOISOTOPES;

EID: 77954795211     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1251-0     Document Type: Review

References (36)

1. Siris S, Miller PD, Barrett-Connor E (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
2. Consensus development conference (1993) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646-650
3. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7(2):221-227
4. Cooper (1997) The crippling consequences of fractures and their impact on quality of life. AM J Med 103(2):12S-19S
5. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
6. Kanis JA, and the WHO Study Group (1994) Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368-381
7. Kanis JA, Melton LJ III, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141
8. US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Rockville, MD
9. van StaaTP D, EM LHG, Cooper C (2001) Epidemiology of fractures in Wales and England. Bone 29:517-522
10. Cooper C, Harvey N, Dennison E (2008) Worldwide epidemiology of osteoporotic fractures. In innovation in skeletal medicine: 95-112. Rizzoli and Reginster ed
11. Cooper C, Atkinson EJ, Kotowicz M, O'Fallon WM, Melton LJ 3rd (1992) Secular trends in the incidence of postmenopausal vertebral fractures. Calcif Tissue Int 51(2):100-104
12. Dempster DW (2006) Anatomy and functions of the adult skeleton. In: Favus MJ, et al, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research:7-11
13. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032
14. Lindsay R, Silverman S, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
15. Brown SA, Rosen CJ (2003) Osteoporosis. Med Clin North Am 87:1039-1063
16. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395-1408
17. available on www.shef.ac.uk/FRAX
18. Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV (2010) Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int 21(5):863-871
19. Hosoi T, WHO FRAX(R) (2009) Usefulness and limitation of FRAX(R) in the practice of internal medicine. Clin Calcium 19 (12):1749-1755
20. Seeman E, Devogelaer JP, Lorenc R et al (2008) Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23(3):433-438
21. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Eng J Med 350(5):459-468
22. Reginster JY, Seeman E, de Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822
23. Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21(4):536-542
24. Bruyère O, Roux C, Badurski J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23(12):3041-3045
25. Reginster JY, Sarlet N, Lejeune E, Leonori L (2005) Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. Curr Osteoporos Rep 3(1):30-34
26. Marie PJ (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int Suppl 1:S7-S10
27. Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol Suppl 1:S11-S15
28. Brennan TC, Rybchyn MS, Green W et al (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291-1300
29. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY (2008) Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther 25(12):1235-1256
30. Ammann P, Shen V, Robin B et al (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012-2020
31. Recker R, Marin F, Ish-Shalom S et al (2009) Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24(8):1358-1368
32. Kendler DL, Adachi JD, Josse RG, Slosman DO (2009) Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporos Int 20(7):1101-1106
33. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17(1):1-10
34. Watts NB, Geusens P, Barton IP, Felsenberg D (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of non-vertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097-2104
35. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment antiresorptive drugs. Am J Med 112(4):281-289
36. Delmas P, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604